John Kastelein
@JohnKastelein
Professor of Medicine , Lipidologist , Trialist in Cardiometabolic Medicine , Entrepreneur in Biotech , Amsterdam , the Netherlands Husband and Father
The curtain is about to rise at #AAIC2025, where full results from the Alzheimer’s biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: bit.ly/4lOSxBO
This paper is so important and puts to rest those jumping on the VLDL/remnant bandwagon at the expense of ignoring LDLs. What everyone needs to do is order apoB, a one-time Lp(a) and then work hard at lowering apoB. The treatments that lower apoB lower both remnant-P and LDL-P…
Het nieuwe handelsakkoord met de Verenigde Staten bevestigt wat al langer zichtbaar is: Europa heeft zijn energie-onafhankelijkheid verloren. Russisch gas is ingeruild voor Amerikaans LNG, duurder, vervuilender, en vooral een nieuwe vorm van structurele afhankelijkheid. Die…
Obicetrapib is a selective CETPi which ⏬ LDL-C by ~36%. Now in @AmericanHeartJ, we discuss the rational/design of the phase 3 REMBRANDT trial which will examine the effect of obicetrapib + ezetimibe on coronary plaque. sciencedirect.com/science/articl… @JohnKastelein @ProfSNicholls
Johnny Cash and John Denver perform "Take Me Home, Country Roads" in their only performance together (1978)
Hot off the press! Excited to share our new publication in #naturemedicine rdcu.be/evDC9 #ANGPTL3 #ANGPTL8 #lipids #ASCVD Targeting the specific ANGPTL3/8 complex to improve several dyslipidemias and possibly reduce residual cardiovascular risk
ESC late breakers you might be interested in Mon- presented by Jessica Schubert & Steve Nicholls. Sat 5.40 Science Box 5 - independent & joint effects of obesity & metabolic abnormalities on ASCVD, HF, MASLD and ESRD in males & females 1.9 m PY FU
Beg, borrow or Steal this paper so you can cruise down BROADWAY - there is a big need for this med 😅🧐- nejm.org/doi/pdf/10.105… @nationallipid @society_eas @ASPCardio @escardio @atherosociety #cholesterol @FamilyHeartFdn @NewAmsPharma
Now what could cause that? 🤔 “The research suggests that "inflammaging"—chronic, low-grade inflammation associated with aging—appears to be a byproduct of industrialized lifestyles and varies significantly across global populations.” “Aging-related inflammation is not…
Treating LDL is going to go the way treating hypertension did Combining multiple agents at lower doses instead of a high dose of one drug For example, Statin + ezetimibe or ezetimibe + CETP inhibitor or statin + PCSK9 inhibitor
Simply increasing statin doses isn’t the best solution for persistently high LDL-C. Doubling the dose only reduces LDL-C by ~6%—a diminishing return even at dramatically higher doses. Combination therapy is significantly more effective for most patients.
Oh yeah ApoM is fascinating and is essential for incorporating small hydrophobic molecules like sphingosine-1 phosphate into HDL...however, there are 5 different S1p receptors!
ApoM? Never heard of it until today. Plays a role in Macular Degeneration? .@TuckerGoodrich @JoshJwageman nature.com/articles/s4146…
Simply increasing statin doses isn’t the best solution for persistently high LDL-C. Doubling the dose only reduces LDL-C by ~6%—a diminishing return even at dramatically higher doses. Combination therapy is significantly more effective for most patients.
Statins serve as a solid start to lipid-lowering therapy, but many patients need more. Doubling the dose only additionally lowers LDL-C by about 6%, and that pattern holds even at 4x and 8x the dose. For many patients struggling with persistently high LDL-C, higher dose statins…
Een onbegrijpelijk besluit van het @parool om @TheodorHolman tegen zijn zin te laten stoppen met zijn column. Diep treurig: de best schrijvende columnist van Nederland. Grote dank voor alle jaren!
Helaas. Tegen mijn zin.
Dag @LodewijkA, je bent het geweten van jouw partij. Nu is het moment om je uit te spreken.
We’re excited to join @NasdaqExchange to wrap up our R&D Day and the trading day by ringing the closing bell. #NasdaqListed
Welcoming @NewAmsPharma to the @NasdaqExchange Closing Bell.
We invite you to join our R&D Day webcast on June 11 beginning at 9am ET. Hear from our leadership team as they discuss the latest developments in our clinical program and the future of innovation in cardiovascular care. bit.ly/43UH5gb
BIG NEWS in the obicetrapib story - fiercebiotech.com/biotech/newams… Patients had significant reductions in the biomarker p-tau217 compared to their counterparts on placebo. The result was statistically significant in the full Alzheimer’s population and in the 367 ApoE4 carriers. Other…
We’re pleased to share positive topline results from our Alzheimer's Disease biomarker analyses in the Phase 3 BROADWAY trial. Full results will be presented on July 30th at #AAIC2025. Learn more about the study: bit.ly/3SIOz0t